News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase II (World)
Medivir (MVRBF) Initiates Clinical Study Of Birinapant In Combination With KEYTRUDA (Pembrolizumab) In Patients With Treatment-Refractory Solid Tumours 8/18/2017
Immunicum Completes Strategic Analysis And Defines Updated Clinical Development Plan For Ilixadencel 8/17/2017
Opthea Presents Additional Positive Data From OPT-302 Phase I/IIa Wet AMD Trial At ASRS Meeting 8/16/2017
Dimerix Limited To Present Analysis Of DMX-200 Phase IIa Clinical Trial In Chronic Kidney Disease At The American Society of Nephrology (ASN) Annual Kidney Week 2017 8/16/2017
Inventiva Release: Odiparcil Awarded Orphan Drug Designation For The Treatment Of MPS VI By The FDA 8/14/2017
Galapagos (GLPG.BR)' Phase II Results With GLPG1690 are 'Extremely Exciting' 8/14/2017
Can-Fite BioPharma (CFBI) Completes Patient Enrolment For Its Phase II Study Of Namodenoson In The Treatment Of Liver Cancer 8/9/2017
Zynerba (ZYNE)’s Failed Cannabidiol Gel Trial Has Upside for Rival GW Pharma (GWPH) 8/8/2017
AIT Therapeutics Announces Enrollment Of First Patient Into Its NO-NTM Abscessus Phase II Trial In Nontuberculous Mycobacteria (NTM) 8/7/2017
Theravance Biopharma (TBPH) Announces Positive Top-Line Results From Phase IIb Study Of Velusetrag (TD-5108) In Patients With Gastroparesis 8/3/2017
Roche (RHHBY)’s Tecentriq Hits Trouble with NICE in Bladder Cancer 8/3/2017
Treatment With Qu Biologics’ Novel Immune Therapy For Ulcerative Colitis Results In High Clinical And Endoscopic Response Rates And Histological Improvement 8/3/2017
Aprea Announces First Patient Enrolled In Phase Ib/II Clinical Study Of APR-246 For The Treatment Of Platinum-Resistant High-Grade Serous Ovarian Cancer 8/2/2017
TRANSGENE (ENX:TNG) Release: First Patient Dosed In A Phase 1/2 Trial Of Pexa-Vec + Opdivo For The First-Line Treatment Of Advanced Liver Cancer 7/31/2017
Tiziana Life Sciences Plc Release: Publication Of Research Article On Foralumab, A Fully Human Anti-Cd3 Antibody Being Developed As An Oral Therapy For Nash And Autoimmune Diseases 7/28/2017
Pluristem Therapeutics (PSTI) Release: New Data From ARS Study Shows Significant Hematological Deficiencies Even At Low Radiation Levels; PLX-R18 Supports Hematological Recovery 7/28/2017
AMO Pharma Receives FDA Orphan Drug Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy 7/27/2017
Oncolytics Biotech (ONC.TO) To Present REOLYSIN Safety Data In Combination With Chemotherapy At ESMO 2017 Congress 7/26/2017
First Patient Enrolled In Oncoquest's Phase I/II Study Combining Oregovomab With Hiltonol In Recurrent Ovarian Cancer 7/26/2017
Verona Pharma (VRP.L) Doses First Patients In Phase IIb Clinical Trial Of RPL554 For COPD Maintenance Treatment 7/26/2017
Pharming Group (PHGUF.PK) Announces Publication Of RUCONEST Prophylactic Data In Lancet 7/26/2017
Theratechnologies (TH.TO) Announces New Findings With The Investigational Antiretroviral Ibalizumab And With EGRIFTA (Tesamorelin For Injection) 7/24/2017
DelMar Pharma Receives Approval From China's Human Genetic Resources Administration To Initiate Phase II Clinical Trial In Newly Diagnosed GBM 7/24/2017
Janssen Sciences Ireland UC Releases: Data Published In Lancet Shows High Efficacy At 96 Weeks For First Investigational Two-Drug, Long-Acting Injectable HIV Regimen 7/24/2017
Merck KGaA (MKGAF.PK) Release: EMA's CHMP Issues Positive Opinion For Avelumab For The Treatment Of Metastatic Merkel Cell Carcinoma 7/21/2017
Uncertainty Hits as Roche (RHHBY) is Dealt Multiple Clinical Trial Setbacks 7/21/2017
BiondVax's Universal Flu Vaccine Meets All Endpoints in Phase IIb Study 7/20/2017
Another Alzheimer's Let-Down as FUJIFILM's Candidate Flunks Phase II Test 7/19/2017
Genentech (RHHBY) R&D Exec Reveals Alzheimer's is Still A Priority 7/19/2017
How Much Money Will These 5 Pharma Companies' Pipelines Generate in 5 Years 7/19/2017
Tiziana Life Sciences Plc Announces Initiation Of A Phase IIa Clinical Trial With Milciclib In Patients With Hepatocellular Carcinoma 7/19/2017
BriaCell Provides Clinical Update On Its Ongoing Phase I/IIa Clinical Study Of BriaVax In Advanced Breast Cancer 7/19/2017
In Alzheimer's, The 'Juggernaut Is Changing Course,' Says TauRx Pharma Chief Exec 7/18/2017
Can-Fite BioPharma (CFBI)’s Phase II NAFLD/NASH Trial With Namodenoson Set To Commence Patient Enrollment Following Conclusion Of Successful Clinical Investigator Meeting 7/17/2017
AXON Neuroscience's Tau Vaccine Has Completed Phase II Enrolment In Alzheimer's 7/17/2017
RedHill Biopharma (RDHL) Announces Last Patient Visit In BEKINDA Phase II Study For IBS-D 7/17/2017
New Experimental Data On Anti-Inflammatory Effects Of ABX464, Abivax (ABVX.PA)'s First-In-Class Drug Candidate To Achieve Functional Cure In HIV-Patients, Published In Nature Scientific Reports 7/13/2017
FDA Grants Orphan Drug Designation To Mallinckrodt (MNK) Development Product For Potential Treatment Of Duchenne Muscular Dystrophy 7/13/2017
Camurus And Braeburn Pharma Announce Topline Phase II Results For Long-Acting Buprenorphine In Opioid Dependent Patients With Chronic Pain 7/12/2017
Vifor Pharma Announces Three Outcomes Trials In Heart Failure And Iron Deficiency 7/12/2017
Dimerix Limited Reports Positive Results From Phase IIa Trial Of DMX-200 In Chronic Kidney Disease 7/12/2017
Why Biogen (BIIB) Spinoff Bioverativ (BIVV)'s Anemia Drug Could Be A Blockbuster 7/11/2017
ProMetic Life Sci (PFSCF.PK) Announces Positive Long Term Clinical Data On Ryplazym In Plasminogen Congenital Deficiency And Provides Regulatory Update 7/11/2017
Oramed (ORMP) Announces End-Of-Phase II Meeting With FDA To Initiate Phase III Program 7/11/2017
uniQure (QURE) Presents New Clinical Data In Hemophilia B Patients Demonstrating Therapeutic Efficacy Of AAV5 Gene Therapy In The Presence Of Pre-Existing Neutralizing Antibodies 7/11/2017
Neovasc (NVC) Announces Positive IDSMB Review For Phase Iib Clinical Trial Of Ifnalpha Kinoid In Lupus 7/11/2017
BioLineRx Announces Initiation Of Phase Ib/II Trial Of BL-8040 In Pancreatic Cancer Under Immunotherapy Collaboration 7/10/2017
AC Immune SA Provides Seven Updates On Its Pipeline And Technology At The Alzheimer's Association International Conference 7/10/2017
Parkinson’s Disease: Prexton Announces Initiation Of Phase II Clinical Testing 7/10/2017
Argenx Presents Full Data From ARGX-111 Phase Ib Study In Patients With Advanced Cancers Over-Expressing The MET Protein At Best Of ASCO Asia 2017 (Singapore) 7/7/2017
Prothena (PRTA) Announces Initiation Of Phase II PASADENA Study Of PRX002/RG7935 In Patients With Early Parkinson’s Disease 7/6/2017
Bay Area's Coherus Dealt Another Blow as Daiichi Sankyo Discontinues Work on RA Drug 7/6/2017
RDD Pharma Receives Orphan Designation For RDD-0315 In Spinal Cord Injury Patients In The European Union 7/5/2017
Galapagos (GLPG.BR) Release: New Phase II Study With Filgotinib In Non-Infectious Uveitis 7/5/2017
BeiGene (BGNE) Initiates Pivotal Trial Of PD-1 Antibody BGB-A317 In China In Patients With Urothelial Cancer 7/5/2017
NOXXON Pharma AG Announces First Patients Treated In Phase I/II Clinical Trial Of Nox-A12 Combined With Keytruda In Metastatic Pancreatic And Colorectal Cancer 7/5/2017
Bionomics Limited (BNO.AX): A Company With Deals On The Horizon 7/5/2017
ObsEva (OBSV) Announces Presentations Related To Its Assisted Reproductive Technology (ART) And Pre-Term Labor (PTL) Development Programs At ESHRE 2017 Annual Meeting 6/29/2017
Can Merck & Co. (MRK) And Novartis AG (NVS)'s Surprise Heart Drug Success Translate To Blockbuster Sales? 6/29/2017
GenKyoTex S.A. Initiates Patient Enrollment Into Phase II Trial Of GKT831 In Primary Biliary Cholangitis 6/29/2017
GOP Congressman Lost $16.7 Million in Single Day on This Tanking Biotech Stock 6/29/2017
Halozyme (HALO) Phase II Data In Advanced Pancreas Cancer Presented At European Society For Medical Oncology Symposium 6/28/2017
Bavarian Nordic (BAVA.CO) Announces Positive Data From Ongoing Phase II Study Investigating A Universal RSV Vaccine 6/27/2017
Xenon Pharma To Host Conference Call And Webcast Today At 9:00 A.M. Eastern Time To Discuss Topline Results From TV-45070 Phase IIb Clinical Trial In PHN 6/27/2017
Results Of NeuroDerm (NDRM)’s ND0612H Phase II Trial Presented In Oral Session At The 3rd Congress Of The European Academy Of Neurology 6/27/2017
Verona Pharma (VRP.L) Receives Regulatory Approval To Commence Phase IIb Clinical Trial Of RPL554 For COPD Maintenance Treatment In Five Countries Across Europe 6/26/2017
European Hematology Association: Clinical And Biologic Covariates Of Outcomes In ZUMA-1: A Pivotal Trial Of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) In Patients With Refractory Aggressive Non-Hodgkin Lymphoma (NHL) 6/26/2017
European Hematology Association: Global Trial Of The Efficacy And Safety Of CTL019 In Adult Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: An Interim Analysis Of The JULIET Study 6/26/2017
European Hematology Association: Multicenter Open-Label Phase 2 Study Of Ibrutinib In Chronic Graft Versus Host Disease (cGVHD) After Failure Of Corticosteroids 6/26/2017
Agios (AGIO) Announces Updated Data From Fully Enrolled DRIVE PK Study Demonstrating AG-348’s Potential As The First Disease-Modifying Treatment For Patients With Pyruvate Kinase Deficiency 6/26/2017
Agios (AGIO) Release: New Data From Phase I/II Trial Of Oral IDHIFA (Enasidenib) Demonstrate Durable Complete Responses In Patients With IDH2 Mutant Relapsed Or Refractory AML 6/26/2017
Mithra Pharmaceuticals Estelle Phase IIb Results On Well-Being And Body Weight Published In Leading Peer-Reviewed Journal 6/26/2017
Braeburn Pharma Release: Phase II Trial Demonstrates Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder 6/23/2017
Bellicum (BLCM) Announces Clinical Data On BPX-501 At Presidential Symposium Of The 22nd Congress Of The European Hematology Association 6/23/2017
Bellicum (BLCM) Reports Clinical Results Of BPX-501 In Pediatric Leukemias At The 22nd Congress Of The European Hematology Association 6/23/2017
Novartis AG (NVS) Pivotal CTL019 6-Month Follow-Up Data Show Durable Remission Rates In Children, Young Adults With R/R B-Cell ALL 6/23/2017
Novartis AG (NVS) Data Shows Half Of Eligible Ph+ CML-CP Patients Remain In Treatment-Free Remission Nearly Two Years After Stopping Tasigna 6/23/2017
Hutchison China MediTech (Chi-Med) Initiates A Phase I/II Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In China 6/22/2017
Zealand Pharma  (ZEAL.CO) Release: Phase IIa Trial Results Support Development Of Dasiglucagon In The ILet Pump System For Type 1 Diabetes 6/22/2017
Herantis Pharma's Lymfactin Study Advances To Last Patient Cohort, Company Announces Initial Plans For Continued Development 6/22/2017
InDex Pharmaceuticals AB Enrolls First Patient In The Phase IIb Study CONDUCT With Cobitolimod 6/21/2017
Kadimastem Received Approval From The Hadassah Hospital IRB (Helsinki Committee) For Conducting A Clinical Trial In ALS Patients 6/21/2017
ErgoMed Release: PeproStat Phase IIb Study Passes Recruitment Mid-Point Ahead Of Schedule 6/21/2017
Ipsen (IPN.PA) And Its Partner Exelixis (EXEL) Announce Independent Radiology Committee Review Confirms Results From Phase II CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma 6/20/2017
Galapagos (GLPG.BR)' R&D Update 2017: Rapidly Advancing Our Product Candidates 6/20/2017
Neovacs Announces The Completion Of Patient Enrollment In Phase IIb Clinical Study Of IFNalpha Kinoid In Lupus 6/20/2017
Galapagos (GLPG.BR)' R&D Update 2017: Rapidly Advancing Our Product Candidates 6/20/2017
GeNeuro Announces First Patient Treated In Phase IIa Study With Gnbac1 In Type 1 Diabetes 6/19/2017
Genexine Co. Ltd. Receives Approval To Initiate Phase Ib/II Trial Of GX-188E, HPV Therapeutic DNA Vaccine, In Combination With KEYTRUDA (Pembrolizumab), For The Treatment Of HPV-Induced Cervical Cancer 6/19/2017
Zealand Pharma  (ZEAL.CO) Release: Glepaglutide Meets Primary Endpoint In Phase II Trial In Patients With Short Bowel Syndrome 6/19/2017
VBL Therapeutics (VBLX) Provides Update On Long-Term Survival In Phase II Trials Of Patients With Multiple Tumor Types 6/19/2017
Why Drug Giants Like Merck & Co. (MRK) and AstraZeneca PLC (AZN) Scientists are Looking in the Toilet for New Cancer Treatments 6/16/2017
MediWound (MDWD) Release: IIndependent Study In Germany Shows NexoBrid Reduces Average Burn Treatment Costs By Nearly 30% Versus Standard Of Care 6/16/2017
Mallinckrodt (MNK) Enrolls First Patient In Phase IIB Trial Of H.P. Acthar Gel (Repository Corticotropin Injection) For Amyotrophic Lateral Sclerosis (ALS) 6/15/2017
Debiopharm Announces Completion Of Enrollment In Phase I/II Clinical Trial With Debio 1143 In SCCHN 6/15/2017
Modra Pharma Announces Start Of Phase II Study For Its Lead Oral Chemotherapy In Patients With Metastatic Prostate Cancer 6/14/2017
GenSight Reports Long-Term Positive Safety And Visual Acuity Results At Week 96 In Phase I/II Study Of GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON) 6/14/2017
Janssen Pharmaceutical Release: Pimodivir Alone Or In Combination With Oseltamivir Demonstrated A Significant Reduction In Viral Load In Adults With Influenza A 6/14/2017
SoCal's Regulus (RGLS) Sinks After AstraZeneca PLC (AZN) Bails on Lead NASH Drug 6/13/2017
Probiodrug AG Announces Encouraging Results Of The Phase IIa SAPHIR Study 6/12/2017
Sophiris Bio (SPHS) Announces That The First Patient Has Been Dosed In Phase IIb Study Of Topsalysin In Patients With Clinically Significant Localized Prostate Cancer 6/8/2017
NovoCure Release: First Patient Enrolled In RTOG Trial Of Optune Together With Bevacizumab For Patients With Bevacizumab-Refractory Recurrent Glioblastoma 6/8/2017
Novartis AG (NVS) Finally Reveals Long-Awaited JULIET CAR-T Data 6/7/2017
Kamada Ltd. (KMDA) Provides Update On Clinical Program For Alpha-1 Antitrypsin IV For Treatment Of Graft-Versus-Host Disease 6/7/2017
Poxel (POXEL.PA) Announces Additional Positive Results For Imeglimin Phase IIb Study In Japan For The Treatment Of Type 2 Diabetes 6/6/2017
MorphoSys AG Presents First Safety And Efficacy Data Of MOR208 In Combination With Lenalidomide From A Phase II Study In DLBCL 6/6/2017
Bristol-Myers Squibb (BMY) Release: Encouraging Disease Control Rates Observed With Nivolumab Alone Or In Combination With Ipilimumab In Refractory Or Relapsing Malignant Pleural Mesothelioma Patients: Results From IFCT-1501 MAPS-2 Trial 6/5/2017
Helsinn And MEI Pharma (MEIP) Report Correlation Between Mutations In DNA Methylation Pathway And Clinical Response In Phase II Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia 6/5/2017
Positive Phase IIb Trial Of Pharmalink AB's Nefecon In Primary IgA Nephropathy Presented At Leading Kidney Disease Conference 6/5/2017
NeuroDerm (NDRM) Presents ND0612H Phase II Trial Results In Late-Breaking Poster Session At The 21st International Congress Of Parkinson’s Disease And Movement Disorders 6/5/2017
HalioDx Highlights Use Of Immunosign To Define CAR T-Cell Therapy Signature In Tumor At ASCO 2017 6/5/2017
Aurinia (AUPH) Presents Additional Data From Phase IIb AURA-LV Study, Demonstrating Stable Renal Function And Blood Pressure Without Electrolyte Complications Through 48 Weeks 6/5/2017
Novartis AG (NVS) Landmark Study Of Tafinlar + Mekinist Demonstrates Durable Survival Benefit At Five Years In Patients With BRAF Mutation-Positive Metastatic Melanoma 6/5/2017
Medical Prognosis Institute - The Efficacy Of Chemotherapy With Epirubicin, One The Of Most Used Drugs In Breast Cancer Can Now Be Predicted By DRP - Poster Published At ASCO 6/5/2017
Prima Biomed (PRR.AX) Release: LAG-3Ig (IMP321) Demonstrates Positive Safety And Efficacy Qualities In Breast Cancer Clinical Trial 6/5/2017
Eisai Company (ESALY.PK) To Present Results Of Phase Ib/II Study Of Anticancer Agent Lenvima (Lenvatinib) In Combination With Anti-PD-1 Antibody Pembrolizumab 6/5/2017
MorphoSys AG Presents Updated Clinical Data For Anti-CD38 Antibody MOR202 In Multiple Myeloma At ASCO 2017 6/5/2017
Vaxon Biotech SA Announces Results Of Its Phase IIb Lung Cancer Trial Of Vx-001, A Therapeutic Vaccine Based On Optimized Cryptic Peptides 6/1/2017
Hepatera: Eligibility To PRIME Scheme Granted To Myrcludex B By The EMA 5/25/2017
6 (Plus 2!) Most Notable ASCO Abstracts So Far 5/24/2017
Kamada Ltd. (KMDA) Presents Updated Data From Phase II Clinical Trial Of Inhaled Alpha-1-Antitrypsin For Treatment Of Alpha-1 Antitrypsin Deficiency At 2017 American Thoracic Society International Conference 5/24/2017
ORYX Reports Positive Clinical Evidence With Oncolytic Virus ParvOryx In Combination With Immuno-Oncology Drugs 5/23/2017
NeuroDerm (NDRM) ND0612H Phase II Trial Results To Be Presented In Late-Breaking Session At The 21st International Congress Of Parkinson’s Disease And Movement Disorders 5/23/2017
Protalix (PLX) Announces Presentation Of Phase II Clinical Trial Results For Alidornase Alfa In Cystic Fibrosis At The 40th European Cystic Fibrosis Society Conference 5/23/2017
Zealand Pharma  (ZEAL.CO) Release: Positive Phase IIa Results With Microdoses Of Dasiglucagon Support Use In A Dual-Hormone Artificial Pancreas System 5/23/2017
AM-Pharma Completes Patient Recruitment Of Recombinant Human Alkaline Phosphatase (recAP) Phase II Trial In Acute Kidney Injury 5/22/2017
Myovant (MYOV) Announces Presentation Of Positive Phase II Data For Relugolix In Women With Endometriosis-Associated Pain At The World Congress On Endometriosis 5/22/2017
Polyphor Announces Successful End Of Phase II Meeting With FDA For Murepavadin In Nosocomial Pneumonia 5/19/2017
Astellas (ALPMY) Announces Oncology Portfolio Updates 5/18/2017
The Lancet Publishes Phase ll Results From Shire (SHPG)'s Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates In Patients With Moderate-To-Severe Ulcerative Colitis 5/18/2017
Data From Prima Biomed (PRR.AX) AIPAC Clinical Trial To Be Presented At 2017 ASCO Conference 5/18/2017
Nanobiotix Announces First Positive Human Data Showing That NBTXR3 Could Become A Backbone In Immuno-Oncology 5/18/2017
Galapagos (GLPG.BR) Release: Seven Abstracts On Filgotinib Accepted By EULAR 2017 5/16/2017
NOXXON Pharma AG Announces Collaboration With National Center For Tumor Diseases In Heidelberg For Nox-A12/Keytruda Phase I/II Combination Trial 5/16/2017
Inventiva Announces Positive Results Of 12 Month Primate Toxicity Study With IVA337 5/16/2017
Summit Therapeutics Completes Enrollment Of Phaseout DMD, A Phase II Clinical Trial Of Ezutromid In Patients With DMD 5/15/2017
Antibe Therapeutics (ATE.V) Engages Topstone Research And Appoints Dr Francis Chan As Key Advisor For Phase II Clinical Trial Of ATB-346 5/12/2017
4 Biotechs That Could Release Stock-Shattering Data Soon 5/11/2017
Biophytis: First Patient-In In The United States And Opening Of 2 Clinical Centers For The SARA-OBS Study On Sarcopenia 5/11/2017
Oncoquest Announces Enrollment Of First Patient In Phase I/II Clinical Study Using Combination Of Oregovomab With Checkpoint Inhibitor Nivolumab In Recurrent Ovarian Cancer 5/9/2017
AiCuris Initiates U.S. Clinical Phase II Trial With Oral Pritelivir For The Treatment Of HSV Infections In Immunocompromised Adults 5/9/2017
Eyevensys Announces The First-In-Human Treatment With Its GroundBreaking EyeCET ElectroTransfection Technology For Eye Diseases 5/9/2017
Myovant (MYOV) Announces Presentation Of Positive Phase II Data For Relugolix In Women With Heavy Menstrual Bleeding And Uterine Fibroids At The Annual Meeting Of The American Congress Of Obstetricians And Gynecologists 5/8/2017
DelMar Pharma Presents New Mechanism Of Action Data For Its Lead Agent VAL-083 In Temozolomide-Resistant Glioblastoma Multiforme (GBM) At The World Federation Of Neuro-Oncology Societies (WFNOS) 5/8/2017
Galapagos (GLPG.BR) Presents Three Posters On Filgotinib In Crohn's Disease At DDW 2017 5/8/2017
4 Biotechs That Could Explode Or Crash In May 5/5/2017
First Patient Enrolled In Mallinckrodt (MNK) Phase II Trial Of StrataGraft Regenerative Skin Tissue 5/5/2017
GENFIT (ALGFT): First Patient Enrolled In A Phase II Trial Recruiting Adults With Primary Biliary Cholangitis (PBC), A Rare Liver Disease 5/5/2017
GENFIT (ALGFT): First Patient Enrolled In A Phase II Trial Recruiting Adults With Primary Biliary Cholangitis (PBC), A Rare Liver Disease 5/5/2017
Poxel (POXEL.PA) Rockets After Diabetes Med Hits Goals In Mid-Stage Study 5/4/2017
Neovacs To Present Clinical Development Update On IFNa Kinoid in Dermatomyositis 5/4/2017
Argenx Reaches 50% Enrollment In Phase II Clinical Trial Of ARGX-113 In Myasthenia Gravis 5/4/2017
GenKyoTex S.A. Announces FDA Approval Of IND For Phase II Trial Of GKT831 In Patients With Primary Biliary Cholangitis 5/3/2017
Abivax (ABVX.PA) Stock More Than Doubles On Mid-Stage HIV Data 5/2/2017
Phase II CoDIFy Trial Results Published In Lancet Infectious Diseases With Data Showing Summit Therapeutics’s Ridinilazole Achieved Statistical Superiority Over Vancomycin In The Treatment Of C. Difficile Infection 5/2/2017
First Ever Evidence Of Treatment-Induced Reduction In HIV Reservoirs:Abx464, Abivax (ABVX.PA) Lead Drug Candidate, Impacted Hiv Blood Reservoir In A Phase IIa Clinical Trial (Abx464-004) 5/2/2017
Summit Therapeutics: Phase II CoDIFy Trial Results Published In Lancet Infectious Diseases 5/2/2017
Living Cell Tech Release: Treatment Completed For All Patients In Parkinson’s Trial 5/1/2017
PIQUR Therapeutics AG Receives EMA Orphan Drug Designation For PQR309 In Diffuse Large B-Cell Lymphoma 4/27/2017
Wilson Therapeutics Presents Promising Neurological Phase 2 Data For WTX101 At American Academy of Neurology Meeting 4/26/2017
Galapagos (GLPG.BR) Announces New Phase II Proof-Of-Concept Study With Filgotinib In Cutaneous Lupus Erythematosus 4/26/2017
ASLAN Initiates Global Pivotal Study For Varlitinib In Biliary Tract Cancer 4/25/2017
Blueberry Therapeutics Commence Phase I/II Clinical Trial Of Lead Product BB2603 4/25/2017
Finally! Novartis AG (NVS) To Release Long-Awaited Juliet CAR-T Data In June 4/25/2017
Vyome Completes Enrollment For Proof Of Concept Clinical Study Of VB 1953 In Patients With Moderate To Severe Acne 4/25/2017
Top 15 R&D Spenders In The World For 2017 4/24/2017
Tiziana Life Sciences Plc Announces Approval Of A Phase II Clinical Trial Protocol For Milciclib In Patients With Hepatocellular Carcinoma 4/24/2017
NGM Announces NGM282 Dramatically Reduced Liver Fat And Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) In Phase II Trial 4/24/2017
Shionogi Presents New Clinical And Non-Clinical Data On S-033188, An Investigational Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza, At The 27th European Congress Of Clinical Microbiology And Infectious Diseases 4/24/2017
Mologen (MOLGF.PK): Positive Subgroup Results Of The Exploratory Phase II IMPULSE Study Of Lefitolimod In Extensive-Disease Small-Cell Lung Cancer (SCLC) 4/24/2017
Akari Therapeutics Demonstrates Positive Response With Coversin In Ongoing Phase II PNH Trial And In Additional Clinical Targets 4/24/2017
Wilson Therapeutics Presented Positive Final Phase II Data For WTX101 At EASL Annual Meeting 4/24/2017
RedHill Biopharma (RDHL) Announces Enrollment Of Last Patient In The BEKINDA Phase II Study For IBS-D 4/24/2017
Aurinia (AUPH) Releases Additional 48-Week Data From The AURA-LV Study During Late-Breaking Session At National Kidney Foundation 2017 Spring Clinical Meetings 4/21/2017
BeiGene (BGNE) Announces Initiation Of First Pivotal Study In China Of PD-1 Antibody BGB-A317 4/21/2017
Laurent Receives FDA And Health Canada Clearance To Initiate APPLAUD Phase II Clinical Study Of LAU-7b For The Treatment Of Cystic Fibrosis 4/19/2017
RedHill Biopharma (RDHL) To Host R&D Day On BEKINDA For Acute Gastroenteritis And IBS-D 4/19/2017
GeNeuro Initiates Phase IIa Study With Gnbac1 In Type 1 Diabetes In Australia 4/19/2017
Shionogi Presents New Data On Cefiderocol (S-649266), A Siderophore Cephalosporin, And S-033188 A Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza At ECCMID 2017 4/18/2017
Circassia (CIR.L) Finally Throws In The Towel On Allergy Program After Trial Failures 4/18/2017
Protalix Biotherapeutics, Inc. (PLX) Announces Positive Results From Phase II Clinical Trial Of Alidornase Alfa (AIR Dnase) For The Treatment Of Cystic Fibrosis 4/12/2017
Argenx Launches Phase II Study Of ARGX-110 As A Monotherapy In Relapsed/Refractory CTCL Patients 4/12/2017
TRANSGENE (ENX:TNG) And Institut Bergonié Start The Phase II Part Of METROmaJX Trial 4/12/2017
3 Drug Giants That Boasts the Best Pipelines 4/11/2017
Inventiva Hits Clinical Milestone With Enrollment Of 100th Patient In IVA337 Phase IIb FASST Trial In Systemic Sclerosis (SSc) 4/10/2017
Medivir (MVRBF) Announces Positive Data From The Phase II Study Of Remetinostat In Patients With Early-Stage Cutaneous T-Cell Lymphoma 4/7/2017
Probiodrug AG Release: Last Patient Last Visit (LPLV) Reached In The SAPHIR Study 4/7/2017
Despite a Mixed PhII, Allergan (AGN) Charges Toward a Late-Stage Depression Study for Botox 4/6/2017
Oncolytics Biotech (ONC.TO)’s REOLYSIN More Than Doubles Overall Survival in Patients With Mutated p53 Metastatic Breast Cancer 4/5/2017
MediGene AG (MDGEF.PK): Academic Partner Presented Compassionate Use Data On AML DC Vaccine At AACR Conference 4/5/2017
ASIT Biotech Announces That It Has Achieved The Primary Endpoint Of The Phase I/IIa Clinical Trial With Its hdm-ASIT+ Product Candidate For House Dust Mite Rhinitis 4/5/2017
Journal Of Diabetes Science And Technology Publishes Scientific Paper Authored By Oramed (ORMP) Scientists 4/4/2017
Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Completion Of Recruitment For Phase IIb Clinical Trials Of Myrcludex B In Chronic Hepatitis Delta 4/4/2017
Galapagos (GLPG.BR) Announces Three New Phase II Proof-Of-Concept Studies With Filgotinib 4/4/2017
Nanobiotix Expands Its Clinical Development In Head And Neck Cancer And I/O 4/4/2017
NovoCure Enrolls Last Patient In STELLAR Trial Testing Tumor Treating Fields In Combination With Standard Of Care Chemotherapy In Mesothelioma 3/31/2017
Akari Therapeutics Announces FDA Fast Track Designation For Coversin 3/31/2017
Opthea Conference Call/Webcast -- Update On OPT-302 Phase 1/2A Wet AMD Clinical Trial 3/31/2017
Johnson & Johnson (JNJ) Stops Mid-Stage Trial For Genmab A/S (GEN.CO)'s Blood Cancer Drug Due To Futility 3/31/2017
Takeda (TKPYY)’s Dengue Vaccine Candidate Elicited Broad Immune Responses In Children And Adolescents Living In Dengue-Endemic Areas; Interim Phase 2 Analysis Published In The Lancet Infectious Diseases 3/30/2017